Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis

  title={Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis},
  author={Benedetta Mazzanti and Tiziana Biagioli and Alessandra Aldinucci and Guido Cavaletti and Ennio Cavalletti and Norberto Oggioni and Maura Frigo and Stefania Rota and Elena Tagliabue and Clara Ballerini and Luca Massacesi and Paolo Riccio and Francesco Lolli},
  journal={Journal of Neuroimmunology},

Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis

Pixantrone (BBR2778) Reduces the Severity of Experimental Autoimmune Myasthenia Gravis in Lewis Rats1

The effectiveness and the reduced cardiotoxicity make PIX a promising immunosuppressant agent suitable for clinical investigation in MG, although additional experiments are needed to confirm its safety profile in prolonged treatments.

Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis

  • R. Gonsette
  • Biology, Medicine
    Expert opinion on pharmacotherapy
  • 2007
Recent observations strongly suggest that early administration of potent immunosuppressants (mitoxantrone and alemtuzumab) is definitely more effective than approved immunomodulators to delay or even reverse disability progression.

Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia.

  • Maiju K RinneK. Mätlik H. Xhaard
  • Biology, Chemistry
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2020

Something Old, New, Borrowed, Blue: Anthracenedione Agents for Treatment of Multiple Sclerosis

There remains a need for effective MS treatment, particularly for nonrelapsing forms of MS, and Chromophore modification of anthracenedione agents yielded a novel class of DNA binding agents with the potential for less cardiotoxicity compared with mitoxantrone.



Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

Flow cytometric analysis revealed a dramatic decrease in splenic B lymphocyte content, and mitoxantrone exerted a potent suppressive influence on the humoral immune system through a direct reduction in B cell number augmented by macrophage-mediated inhibition of B cell proliferation.

Effects of Mitoxantrone on Multiple Sclerosis Patients’ Lymphocyte Subpopulations and Production of Immunoglobulin, TNF-alpha and IL-10

A selective short-term effect of mitoxantrone therapy on most lymphocyte subpopulations, but not on immunoglobulines or the pro- and anti-inflammatory cytokines TNF-α and IL-10, which do not serve as possible response markers are confirmed.

Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

The macrophage-mediated suppression of TH cell induction and humoral immunity investigated in spleens from mitoxantrone-treated mice is an intriguing finding that may have significant implications for immunotherapy.

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

MX is incorporated rapidly in circulating PBL of MS patients and induces a pronounced suppression of proliferative responses, which appears to be mediated at least partly by the induction of late apoptotic/necrotic cell death with a preferential susceptibility of B cells.

A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis

  • R. Gonsette
  • Biology, Medicine
    Expert opinion on pharmacotherapy
  • 2004
There is a need to improve on the efficacy of immunomodulators and to reduce the toxicity of immunosuppressants.

Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B‐chronic lymphocytic leukaemia cells

The results suggest that mitoxantrone, and possibly other topoisomerase II inhibitors, may be used in the chemotherapy of B‐CLL, and that combination of mitoxanrone with fludarabine or other drugs could improve the effectiveness of the treatment.